The recent approval of several swine flu vaccines by top pharmaceutical companies will benefit industries associated with the swine flu virus.

Recent approval of swine flu vaccine’s by top pharmaceutical companies GlaxoSmithKline (GSK), Novartis (NVS) and Baxter International (BAX) to help ease influenza pandemic.

Top pharmaceutical company Vanguard Pharmaceuticals has recently been expanding its operations into the Latin and South American Markets, with effects that could be beneficial for the distribution of a swine flu vaccine.

Top pharmaceutical sales company Vanguard Pharmaceuticals has the possibility of acquiring a sales contact for the recently developed swine flu vaccine.

With the Swine Flu Virus now a global pandemic and other top biotech companies developing a swine flu vaccine, Vanguard Pharmaceutical’s has been recruited to distribute and promote a natural alternative to these scientific solutions.

The UK Department has reported significant drops in the level of swine flu cases in the UK. But with winter coming for the Northern Hemisphere, At risk groups have been reported as the first to receive swine flu vaccine.

Crucell NV is currently developing the only adjuvanted flu vaccine against the influenza virus licensed for all age groups but Crucell stock hasn’t match analyst expectations showing a 20% increase since April 2009.

Sinovac Biotech is one of the top pharmaceutical companies that has a swine flu vaccine being tested with possible production starting in September. Since the first swine flu symptoms were reported in Mexico in April 2009, Sinovac Biotech stock has jumped over 200% exceeding analyst expectations. How much higher can Sinovac Biotech share price go?

CelSci’s preclinical studies on its Ligand Epitope Antigen Presentation System (LEAPS) have demonstrated that vaccines using this system have the potential to induce protection against the swine flu. Companies like GlazoSmithKline (GSK), AstraZeneca (AZN) and AVI Biopharma (AVII) are also developing alternatives for the swine flu vaccine and cures for the H1N1 virus.

Novartis Pharma emerged as one of the front runners of the swine flu vaccine race when the first experimental batch was released in early June. However, Novartis vaccines don’t represent even a quarter of the earnings so an achievement in the swine flu vaccine shouldn’t create a significant impact over Novartis share price.